Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
October 01 2019 - 7:00AM
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming
presentations at the following medical and investor conferences in
October.
Upcoming Medical
Conferences:
- An oral presentation highlighting Phase 1/2 results, including
cohort 4, for AT-GAA for Pompe disease will be included at the 24th
International Congress of the World Muscle Society to be held
October 1-5, 2019 in Copenhagen, Denmark.° Oral
Platform Presentation: Friday, October 4, 10:00 a.m. CEST (4:00
a.m. ET): First-in-human study of ATB200/AT2221 in
patients with Pompe disease: 24-month functional assessment results
from the ATB200-02 trial – Benedikt Schoser, MD, Friedrich-Baur
Institute, Deptartment of Neurology, Ludwig-Maximilians-University
of Munich, Germany.
- A poster presentation highlighting interim clinical results for
the first gene therapy in CLN6 Batten disease will be included at
the 48th Annual Meeting of the Child Neurology Society to be held
October 23-26, 2019 in Charlotte, NC.° Poster
Sessions: Thursday, October 24, 4:00-5:30 p.m. ET and Friday,
October 25, 7:00-8:15 a.m. ET: Interim Results from the
First Clinical Gene Therapy Trial for CLN6 Batten Disease – Emily
de los Reyes, MD, Pediatric Neurologist, Nationwide Children’s
Hospital, Columbus, OH. (Poster #204)
Upcoming Investor
Conferences:
- John F. Crowley, Chairman and Chief Executive Officer, will
participate in a fireside chat at the Cantor Fitzgerald Global
Healthcare Conference in New York, NY on Wednesday, October 2, 2019
at 8:20 a.m. ET.
- Amicus team members and external speakers will present during
the Amicus Analyst Day on Thursday, October 10, 2019 in New York,
NY at 8:30 a.m. ET.
A live audio webcast of the presentations during
the investor conferences and Amicus Analyst Day can be accessed via
the Investors section of the Amicus Therapeutics corporate website
at http://ir.amicusrx.com/events-and-presentations, and will be
archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases. For more information please visit the
company’s website at www.amicusrx.com, and follow on Twitter and
LinkedIn.
CONTACTS:
Investors:Amicus TherapeuticsSara Pellegrino,
IRCVice President, Investor
Relations spellegrino@amicusrx.com(609) 662-5044
Media:Christopher Byrne Executive Director,
Corporate Communications cbyrne@amicusrx.com609-662-2798
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024